The American Cancer Society (ACS) concludes that the benefits of PSA-based screening for prostate cancer outweigh the harms, recommending biennial screening from ages 50–69 for average-risk men; annual screening from ages 45–69 for Black men and non-Black men with a strong family history; biennial screening from ages 45–69 for non-Black men with a single first-degree relative diagnosed at 65 or older, and individualized decisions for men aged 70–74, while screening is not recommended for men with a life expectancy under 10 years and should stop at age 75. Before initiating screening, clinicians should inform patients about the benefits, limitations, and harms of screening, the potential follow-up evaluations of elevated PSA levels, and the expectation that low-risk cancers will initially be managed with active surveillance. Most men with elevated PSA confirmed on repeat testing should be offered magnetic resonance imaging and/or a validated biomarker test to guide biopsy decisions. Source: https://acsjournals.onlinelibrary.wiley.com/
